Associated Papers
Q148N, a Novel Integrase Inhibitor Resistance Mutation Associated with Low-Level Reduction in Elvitegravir Susceptibility.
Varghese V et al.
Aids Research and Human Retroviruses, 2016
In Vivo validation of a bioinformatics based tool to identify reduced replication capacity in HIV-1.
Kitchen CM et al.
The Open Medical Informatics Journal, 2010
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
Ntemgwa M et al.
Antimicrobial Agents and Chemotherapy, 2007
Short communication: low prevalence of genotypic drug resistance mutations among antiretroviral-naive HIV type 1 patients in Malaysia.
Tee KK et al.
Aids Research and Human Retroviruses, 2006
Molecular and functional analysis of intragenic SMN1 mutations in patients with spinal muscular atrophy.
Sun Y et al.
Human Mutation, 2005
Diversity of human immunodeficiency virus type 1 subtype A and CRF03_AB protease in Eastern Europe: selection of the V77I variant and its rapid spread in injecting drug user populations.
Roudinskii NI et al.
Journal of Virology, 2004
Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay.
Kapoor A et al.
Journal of Virology, 2004
Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.
Bally F et al.
Aids Research and Human Retroviruses, 2000
Select a paper to view details